Thioethers

LianBio Appoints Pascal Qian as General Manager of China

Retrieved on: 
Monday, August 2, 2021
Health, Biotechnology, Chemical compounds, Organic compounds, Aminopyridines, Thioethers, Chloroarenes, Specialty drugs, Protein kinase inhibitors, Palbociclib, Sunitinib, Axitinib, Crizotinib, Qian

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.

Key Points: 
  • LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.
  • Mr. Qian has extensive experience launching products in China, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair.
  • He has also led new product development initiatives in China for multiple globally developed drugs, including crizotinib, axitinib and palbociclib.
  • Mr. Qian most recently served as the Vice President, Head of Oncology Business Unit, at Lilly China.

Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021

Retrieved on: 
Monday, July 26, 2021
International Space Station, Clindamycin, Organochlorides, Thioethers, Compagnies Républicaines de Sécurité, Clinical medicine, Commercial Resupply Services, Bacterial vaginosis, Medicine, Chemistry

SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, PhD, the company’s Chief Scientific Officer, will present data from preclinical and clinical studies related to DARE-BV1 at the 2021 Controlled Release Society (CRS) Virtual Annual Meeting on July 27th. Daré submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for DARE-BV1 for the treatment of bacterial vaginosis in June of 2021.

Key Points: 
  • DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
  • Find out more information about the 2021 CRS Virtual Annual Meeting by visiting the CRS website: https://www.controlledreleasesociety.org/events/2021-crs-virtual-annual-... .
  • Dr. Friends presentation will be available following the conclusion of the 2021 CRS Virtual Annual Meeting under Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com .
  • Dar cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Retrieved on: 
Thursday, July 1, 2021
Health sciences, Clinical research, Medical research, Health, Clinical trials, Medical statistics, Devimistat, Thioethers, Futility, Intention-to-treat analysis

25 and based on the 142 within the intention to treat population, the trial was determined to be non-futile.

Key Points: 
  • 25 and based on the 142 within the intention to treat population, the trial was determined to be non-futile.
  • The findings from this interim futility analysis further solidify the potential that devimistat holds in safely and effectively treating AML and other hard-to-treat cancers, said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals.
  • As we continue to advance devimistat through clinical trials, we remain hopeful for the cancer community.
  • The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements.

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer

Retrieved on: 
Tuesday, June 29, 2021
Medical specialties, Clinical medicine, Medicine, Digestive system, Hepatology, Devimistat, Thioethers, Bile duct, Orphan drugs, Bile, Ontuxizumab, Vadastuximab talirine

CRANBURY, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for CPI-613 (devimistat) for the treatment of biliary cancer.

Key Points: 
  • CRANBURY, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for CPI-613 (devimistat) for the treatment of biliary cancer.
  • Biliary cancer appears when cancer cells form in the bile ducts or gallbladder, an essential aspect of the gastrointestinal system.
  • The orphan drug designation for devimistat showcases the importance of discovering these new treatment options.
  • Devimistat has been granted orphan drug status by the FDA for the treatment of pancreatic cancer, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Burkitts lymphoma, peripheral T-cell lymphomas, and soft tissue sarcoma, and now, biliary cancer.

Baum Hedlund Announces Leadership of California Zantac JCCP

Retrieved on: 
Tuesday, June 15, 2021
Chemical compounds, H2 receptor antagonists, Drugs, Furans, Hepatotoxins, Ranitidine, Thioethers, Organic compounds, Roundup

The Presiding Judge of the California Superior Court then assigned Judge Winifred Y. Smith as the Coordination Trial Judge.

Key Points: 
  • The Presiding Judge of the California Superior Court then assigned Judge Winifred Y. Smith as the Coordination Trial Judge.
  • Judge Smiths order appoints trial attorneys R. Brent Wisner of Baum Hedlund Aristei & Goldman and Jennifer Moore (also admitted to practice law in California) of the Moore Law Group to the Zantac JCCP leadership as Plaintiffs Liaisons.
  • With the federal Zantac MDL and the new Ranitidine Product Cases JCCP in California state court, we are following the same path that we took with Roundup, says Wisner.
  • Individuals diagnosed with various forms of cancer after regularly taking Zantac may be eligible to pursue a case in the California Ranitidine Product Cases JCCP 5150.

Global Amino Acids Market (2020 to 2026) - Key Players Include Adisseo France, Aijnomoto and Newtrend Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
General Health, Chemicals, Plastics, Health, Manufacturing, Amino acids, Methionine, Thioethers, Evonik Industries, Wesseling

Ningxia Unisplendour Tianhua Methionine Co., Ltd. (China)

Key Points: 
  • Ningxia Unisplendour Tianhua Methionine Co., Ltd. (China)
    Shijiazhuang Donghua Jinlong Chemical Co., Ltd. (China)
    Evonik Concentrates Methionine Production at Three Locations and Ends Production at Wesseling, Germany
    Evonik Resumes Production of Methionine in Antwerp, Belgium
    Adisseo Commences Construction of 180K Tons/Annum Liquid Methionine Plant in Nanjing, China

Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program

Retrieved on: 
Wednesday, May 26, 2021
Devimistat, Thioethers, FOLFIRINOX, Pancreatic cancer, Clinical medicine, Oncology, Cancer

These presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer.

Key Points: 
  • These presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer.
  • The data continues to show us hope for the future, with our continued commitment to patients at the forefront.
  • Title: Abstract #TPS4176: A phase II open-label study of CPI-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.
  • Its an honor to be able to present our ongoing research in pancreatic cancer at one of the most renowned meetings in clinical oncology.

Albendazole Market by Target Pathogen, End-use and Distribution Channel - Global Forecast up to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Health, Pharmaceutical, Articles, Albendazole, Anthelmintics, Benzimidazoles, Carbamates, Thioethers, Online pharmacy, Distribution, Economy, Industry economics)

The "Albendazole Market based on Target Pathogen, End-use and Distribution Channel and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Albendazole Market based on Target Pathogen, End-use and Distribution Channel and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Albendazole Market is projected to grow at the rate of 7.4% CAGR by 2026.
  • On the other hand, the negative effects of albendazole drugs are likely to hamper the albendazole market growth potential.
  • Online pharmacies are the significant distribution channel in the albendazole market due to the rising online purchases and the availability of various drugs in online pharmacies.

2021 Global Toltrazuril (CAS 69004-03-1) Industry - Key Manufacturers and Distributors - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 27, 2021
Agriculture, Natural Resources, Pets, Consumer, Business process, Thioethers, Toltrazuril, Market research, Organic compounds, Chemical compounds, Chemistry

b'The "Toltrazuril (CAS 69004-03-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis global report is a result of industry experts\' diligent work on researching the world market of Toltrazuril.

Key Points: 
  • b'The "Toltrazuril (CAS 69004-03-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis global report is a result of industry experts\' diligent work on researching the world market of Toltrazuril.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.\nThe Toltrazuril global market report key points:\n'

Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

Retrieved on: 
Monday, April 26, 2021
Anti-acne preparations, Sexually transmitted diseases and infections, Probiotics, Clindamycin, Organochlorides, Thioethers, Bacterial vaginosis, Organ systems, Chemistry, Drugs

DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.

Key Points: 
  • DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
  • Patients were evaluated during three clinic visits: Day 1 (screening and randomization visit), Day 7-14 (assessment visit), and Day 21-30 (test-of-cure visit).
  • \xe2\x80\x9cIn the DARE-BVFREE trial, DARE-BV1 was well-tolerated and demonstrated clinical cure efficacy rates superior to those shown by current branded prescription products for treatment of bacterial vaginosis.
  • You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.